Clinical Trials Browser

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT06494150 2026-02-23

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Phase 2 Recruiting

37 enrolled

Gynecologic

Ovarian Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Phase 2 Recruiting

28 enrolled

Breast

ER-Positive Breast Cancer

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06663072 2026-01-09

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Phase 1 Recruiting

25 enrolled

Adenoma, Islet Cell

NCT06110793 2025-12-17

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

49 enrolled

Breast

Breast Neoplasms

NCT07117630 2025-12-05

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

15 enrolled

Breast

Breast Neoplasms

NCT07180160 2025-11-18

ITHRAN

Phase 2 Recruiting

123 enrolled

Breast

Advanced Breast Cancer

NCT05608252 2025-10-29

VS-6766+Abema+Fulv in Met HR+/HER- BC

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05113368 2025-08-21

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Phase 2 Recruiting

31 enrolled

Gynecologic

Ovarian Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Phase 2 Recruiting

50 enrolled

Breast

Breast Neoplasms

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

Phase 2 Recruiting

90 enrolled

Breast

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

Phase 4 Recruiting

300 enrolled

Breast

Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05536128 2025-04-17

Post-CDK

Phase 2 Recruiting

64 enrolled

Breast

Advanced Breast Cancer

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

NCT05816655 2025-03-18

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Recruiting

202 enrolled

Breast

Breast Neoplasms

NCT06856200 2025-03-04

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase NA Recruiting

36 enrolled

Breast

Advanced HR - Positive, HER2 - Negative Breast Cancer

NCT06734533 2024-12-16

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Recruiting

80 enrolled

Breast

HR+ Breast Cancer

NCT04985266 2024-12-05

TRAK-ER

Phase 2 Recruiting

1,100 enrolled

Breast

ER+ Breast Cancer

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

620 enrolled

Breast

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Phase 3 Recruiting

184 enrolled

Breast

Advanced Breast Cancer

NCT04263298 2022-09-30

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Phase 3 Recruiting

210 enrolled

Breast

Breast Neoplasms

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasm Female

Clinical Trials

RaPhLRR

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

GERTRUDE

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

ITHRAN

VS-6766+Abema+Fulv in Met HR+/HER- BC

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

CAMERAN

MINERVA

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Post-CDK

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

TRAK-ER

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer